Nearly Four Million Medicare Beneficiaries Could Be Eligible for the Temporary Medicare GLP-1 Bridge Program Covering These Drugs for Weight Loss - Summary - MDSpire
Advertisement
Nearly Four Million Medicare Beneficiaries Could Be Eligible for the Temporary Medicare GLP-1 Bridge Program Covering These Drugs for Weight Loss
To analyze the eligibility of Medicare beneficiaries for the new GLP-1 Bridge Program for weight loss medications.
Approach:
Analysis Method: KFF analysis based on claims data from 2023.
Key Findings:
3.8 million Medicare beneficiaries meet the eligibility criteria for the GLP-1 Bridge Program, which includes having a BMI of 35 or more, or a BMI of 27 or more with specific comorbid conditions.
The program will cover three GLP-1 medications: Wegovy, Zepbound, and Foundayo.
Eligibility is limited to Part D enrollees who do not have conditions treated by GLP-1 drugs currently covered under Part D.
Interpretation:
The program is set to run for 18 months from July 1, 2026, to December 2027, with varying potential costs to Medicare based on participation rates.
Limitations:
Eligibility is restricted to a subset of Medicare beneficiaries who meet specific clinical criteria, not all with obesity or overweight.
Conclusion:
The GLP-1 Bridge Program may provide significant coverage for eligible Medicare beneficiaries seeking weight management.
